Table 2.
Study that reported the onset time of checkpoint inhibitor pneumonitis (CIP) in NSCLC patients with PD-1/PD-L1 blockade.
| Published Year | Treatment | Study type | Enrollment a | NSCLC stage | Incidence, n (%) | Median time to onset, week(range) | Reference | |
|---|---|---|---|---|---|---|---|---|
| Any grade | High grade (≥3) | |||||||
| 2015 | Nivolumab | Prospective, RCT | 131 | III | 6 (5.0) | 1 (1.0) | 15.1 (2.6–85.1) | (15) |
| 2015 | Nivolumab | Prospective, RCT | 287 | III | 10 (3.5) b1 | 4 (1.4) b2 | 31.1 (11.7-56.9) | (16) |
| 2015 | Pembrolizumab | Prospective, RCT | 550 | IIIB or IV | 21 (3.8) | 11 (2.0) | 8.1 (0.6-56.1) | (18) |
| 2017 | Nivolumab (mono or combined with chemotherapy) |
Retrospective | 111 | IV or recurrent | 8 (7.2) b3 | 4 (3.6) b3 | 5.2 (2.3–24) | (34) |
| 2018 | Nivolumab/Pembrolizumab/Durvalumab (mono or combined with other ICI/chemotherapy) |
Retrospective | 205 | all | 39 (19.0) | 24 (11.7) | 11.7 (2.9–26.1) c | (35) |
| 2020 | Nivolumab (mono or combined with chemotherapy) |
Retrospective | 901 | all | 94 (10.4) | 39 (4.3) | 8.4 (0-75.1) | (36) |
| 2020 | Nivolumab/Ipilimumab/Pembrolizumab (mono or combined with chemotherapy) |
Retrospective d | 205 | all | 5 (2.4) e | 2 (1.0) e | 52.9 (34-86.6) | (37) |
NSCLC, non-small-cell lung cancer; PD-1, programmed cell death 1; PD-L1, programmed cell death ligand 1.
aPatients enrolled in and received ICI treatment.
bIncludes patients with interstitial lung disease (2 in a1, 1 in a2, all in a3).
cInterquartile range of onset time.
dA retrospective study on Chronic pneumonitis (clinical pneumonitis persisting or worsening with steroid tapering and necessitating ≥12 weeks of immune suppression after ICI discontinuation).
eInitial pneumonitis grade.